Broker tips: GSK, Astrazeneca, Vodafone
Berenberg said GSK's evolution was "undervalued", noting that 10 of its 11 novel phase—III assets had been sourced externally under new chief executive Luke Miels. It argued that six late—stage programmes each carried potential peak sales of at least £2bn, helping to restock the pipeline and improv…